Centessa Pharmaceuticals plc (CNTA)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-05

Key Insights

The filing content appears to be truncated XBRL metadata without substantive financial data, making it impossible to assess actual Q1 2026 revenue trends, expenses, or operational performance.
The presence of Genmab AS license agreements (dated 2025-02-14) indicates active licensing partnerships, though specific terms, milestones, or financial impact details are not visible in the provided excerpt.
Cash position and investment portfolio details are referenced across multiple fair value measurement levels, but actual dollar amounts and liquidity metrics are not displayed in the truncated filing content.
The filing references equity instruments (restricted stock, RSUs, employee stock options) and at-the-market offering programs, suggesting ongoing capital structure management, but specific dilution impacts cannot be quantified from the provided data.

Current Report Filed: 2026-03-31

Key Insights

Centessa Pharmaceuticals has agreed to be acquired by Eli Lilly and Company for $38 per share in cash, plus up to $9 per share in contingent value rights (CVRs) tied to the achievement of certain milestones.
The transaction has been recommended by the boards of directors of both Centessa and Eli Lilly, and is subject to customary closing conditions including shareholder approval.
The agreement provides for the cancellation of Centessa's outstanding equity awards, with holders of options and restricted stock units to receive a combination of cash and CVRs.

Annual Report Filed: 2026-03-31

Key Insights

Centessa Pharmaceuticals reported a significant increase in revenue and profitability in 2025, indicating strong growth and performance.
The company secured several new licensing agreements and strategic partnerships during the year, which could drive future product development and commercialization.
Centessa has a robust pipeline of drug candidates in various stages of clinical development, suggesting a promising future for the company.

Insider Trading Filed: 2026-03-27

Key Insights

The reporting person, Karen M. Anderson, exercised stock options for 41,076 ordinary shares and then sold the same amount of shares, indicating insider selling activity.
The sale of shares was executed pursuant to a pre-planned 10b5-1 trading plan, suggesting the transactions were part of a structured strategy rather than a one-off event.
The sale price of $30.1242 per share represents a significant premium over the $8.01 exercise price of the stock options, indicating the reporting person was able to realize substantial gains from the transaction.

Insider Trading Filed: 2026-03-18

Key Insights

The Chief People Officer, Karen M. Anderson, exercised and sold a significant number of Centessa Pharmaceuticals stock options on March 16 and 17, 2026, suggesting potential insider selling activity.
The sales were executed pursuant to a pre-arranged 10b5-1 trading plan, indicating the transactions were part of a planned strategy rather than opportunistic.
The sale prices suggest the shares were sold at a premium to the exercise price, potentially generating substantial gains for the insider.

Current Report Filed: 2026-02-13

Key Insights

Centessa Pharmaceuticals announced the departure of its CEO, Saurabh Saha, M.D., Ph.D., who will transition to an advisory role, providing strategic guidance to the company.
The company has entered into an Advisory Agreement with Dr. Saha, compensating him on an hourly basis for his advisory services over an initial six-month period.
Under the Separation Agreement, Dr. Saha will receive accelerated vesting of his equity grants, a bonus payment, and continued eligibility for company benefits, in lieu of any other severance payments.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.